XML 20 R10.htm IDEA: XBRL DOCUMENT v3.25.2
Revenue from Contracts with Customers
 3 Months Ended
Jul. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
Oncology Revenue
The following table represents disaggregated revenue for the three months ended July 31, 2025 and 2024 (in thousands):
Three Months Ended
July 31,
 20252024
Pharmacology services$13,230 $13,069 
TOS data license revenue311 — 
Other TOS revenue454 992 
Total oncology revenue$13,995 $14,061 
Translational Oncology Solutions ("TOS") license revenue represents revenue from the sale of a license to access certain of the Company's PDX data. Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services and software-as-a-service ("SaaS") provided via our Lumin Bioinformatics software ("Lumin").